An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working Group.

Autor:	Nester CM; Department of Pediatrics, Stead Family Children's Hospital, University of Iowa, Iowa City, Iowa, USA., Feldman DL; National Kidney Foundation, New York, New York, USA., Burwick R; San Gabriel Valley Perinatal Medical Group, Division of Maternal Fetal Medicine, Pomona Valley Hospital Medical Center, Pomona, California, USA., Cataland S; Department of Medicine, The Ohio State University, Columbus, Ohio, USA., Chaturvedi S; Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Cook HT; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK., Cuker A; Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Dixon BP; Renal Section, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA., Fakhouri F; Service of Nephrology and Hypertension, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Hingorani SR; Division of Nephrology, Department of Pediatrics, University of Washington School of Medicine and Seattle Children's Hospital, Seattle, Washington, USA., Java A; Division of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA., van de Kar NCAJ; Department of Pediatric Nephrology, Radboud University Medical Center, Amalia Children's Hospital, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands., Kavanagh D; National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK., Leung N; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA., Licht C; Division of Nephrology, The Hospital for Sick Children, Toronto, Ontario, Canada., Noris M; Istituto di Ricerche Farmacologiche Mario Negri IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Bergamo, Italy., O'Shaughnessy MM; Department of Nephrology, Galway University Hospitals, Galway, Ireland., Parikh SV; Division of Nephrology, Department of Medicine, University of Texas Southwestern, Dallas, Texas, USA., Peyandi F; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre and Fondazione Luigi Villa, Milan, Italy; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy., Remuzzi G; Istituto di Ricerche Farmacologiche Mario Negri IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Bergamo, Italy., Smith RJH; Department of Pediatrics, Stead Family Children's Hospital, University of Iowa, Iowa City, Iowa, USA., Sperati CJ; Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Waldman M; Kidney Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA., Walker P; Arkana Laboratories, Little Rock, Arkansas, USA., Vivarelli M; Laboratory of Nephrology, Division of Nephrology, Clinical Trial Center, Bambino Gesù Children's Hospital IRCCS, Rome, Italy. Electronic address: marina.vivarelli@opbg.net.
Jazyk:	angličtina
Zdroj:	Kidney international [Kidney Int] 2024 Sep; Vol. 106 (3), pp. 326-336.
DOI:	10.1016/j.kint.2024.05.021
Abstrakt:	The term atypical hemolytic uremic syndrome has been in use since the mid-1970s. It was initially used to describe the familial or sporadic form of hemolytic uremic syndrome as opposed to the epidemic, typical form of the disease. Over time, the atypical hemolytic uremic syndrome term has evolved into being used to refer to anything that is not Shiga toxin-associated hemolytic uremic syndrome. The term describes a heterogeneous group of diseases of disparate causes, a circumstance that makes defining disease-specific natural history and/or targeted treatment approaches challenging. A working group of specialty-specific experts in the thrombotic microangiopathies was convened to review the validity of this broad term in an era of swiftly advancing science and targeted therapeutics. A Delphi approach was used to define and interrogate some of the key issues related to the atypical hemolytic uremic syndrome nomenclature. (Copyright © 2024 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu